Improving melanoma classification by integrating genetic and morphologic features - Wikidata - awgldk - TriplyDB

Improving melanoma classification by integrating genetic and morphologic features

Improving melanoma classification by integrating genetic and morphologic features

http://www.wikidata.org/entity/Q33340639

about

Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma Frequencies of BRAF and NRAS mutations are different in histological types and sites of origin of cutaneous melanoma: a meta-analysis.NRAS mutation status is an independent prognostic factor in metastatic melanoma.Genetics of melanocytic nevi Integrative analysis of epigenetic modulation in melanoma cell response to decitabine: clinical implications Comparison of clinicopathologic features and survival of histopathologically amelanotic and pigmented melanomas: a population-based study.Interface of signal transduction inhibition and immunotherapy in melanoma.Differential volatile signatures from skin, naevi and melanoma: a novel approach to detect a pathological process.Melanoma: what are the gaps in our knowledge.Molecular pathogenesis of sporadic melanoma and melanoma-initiating cells.Correlation of somatic mutations and clinical outcome in melanoma patients treated with Carboplatin, Paclitaxel, and sorafenib Molecular alterations in clinical stage III cutaneous melanoma: Correlation with clinicopathological features and patient outcome.A phase II trial of sorafenib in metastatic melanoma with tissue correlates.Reflectance confocal microscopy features of BRAF V600E mutated thin melanomas detected by immunohistochemistry Ultraviolet radiation accelerates BRAF-driven melanomagenesis by targeting TP53 Comparison of Melanoma Subtypes among Korean Patients by Morphologic Features and Ultraviolet Exposure.A novel miR-451a isomiR, associated with amelanotypic phenotype, acts as a tumor suppressor in melanoma by retarding cell migration and invasion A brief history of melanoma: from mummies to mutations RACK1, a clue to the diagnosis of cutaneous melanomas in horses.Molecular pathogenesis of malignant melanoma: a different perspective from the studies of melanocytic nevus and acral melanoma.Superficial spreading and nodular melanoma are distinct biological entities: a challenge to the linear progression model.Dabrafenib and its potential for the treatment of metastatic melanoma.Vemurafenib: an evidence-based review of its clinical utility in the treatment of metastatic melanoma Expression of sorafenib targets in melanoma patients treated with carboplatin, paclitaxel and sorafenib.Copy number gains in 11q13 and 8q24 [corrected] are highly linked to prognosis in cutaneous malignant melanoma.Acral lentiginous melanoma: incidence and survival patterns in the United States, 1986-2005.Genetic and morphologic features for melanoma classification BRAF mutations in cutaneous melanoma are independently associated with age, anatomic site of the primary tumor, and the degree of solar elastosis at the primary tumor site.A phase 2 trial of complete resection for stage IV melanoma: results of Southwest Oncology Group Clinical Trial S9430 Histologic features of melanoma associated with CDKN2A genotype.Prognostic parameters for the primary care of melanoma patients: what is really risky in melanoma?Clinical and Histopathological Characteristics between Familial and Sporadic Melanoma in Barcelona, Spain.Biomarkers as key contributors in treating malignant melanoma metastases.Polymorphisms in nevus-associated genes MTAP, PLA2G6, and IRF4 and the risk of invasive cutaneous melanoma.The role of melanoma tumor-derived nitric oxide in the tumor inflammatory microenvironment: its impact on the chemokine expression profile, including suppression of CXCL10.Association Between NRAS and BRAF Mutational Status and Melanoma-Specific Survival Among Patients With Higher-Risk Primary Melanoma.The potential for BRAF V600 inhibitors in advanced cutaneous melanoma: rationale and latest evidence The immune-related role of BRAF in melanoma.Targeting mutant BRAF in melanoma: current status and future development of combination therapy strategies The current state of targeted therapy in melanoma: this time it's personal

P2860

Q24607661-99BCC953-3677-4067-82F1-49586583ACFA Q27851617-D47FD856-F8F4-43B7-A05C-48B464752B3C Q27851695-C2F58284-5145-4D7D-9891-C8C6E0F521A4 Q28085036-0713F84B-5C2D-4BDC-9488-ECCE7B0EB473 Q28474843-DDA616AC-6FEB-48B5-81AD-DE254594D31E Q30366026-5223D133-B4B3-4E3E-ADB4-206C26ADEA8D Q30429380-EE038D9C-B033-424A-990A-7AE9F29E0562 Q30991996-FC00D567-1A16-426F-A52D-D9B764111CB5 Q33340645-1BDC2346-CD3B-4998-AC0D-ADE68C102951 Q33725172-C9296FEA-5503-4401-B80B-91DD03A4C693 Q33758211-0A1A6754-6DF1-4717-B70F-818661DC865B Q33778554-8A0D8627-0A02-4107-B231-F4DE8A397E31 Q33785790-50829336-1417-4C99-9D06-1278A14699B9 Q33852985-B592F817-E67F-4BC9-8F93-F183DC0334B1 Q33955442-9A447F90-22EA-4576-AA40-CDDF86F4D5D9 Q34054383-C4A7AABD-A753-408F-B4F2-0B7039D698B6 Q34215802-EAD96EEA-566E-45F4-BBAD-07491365681C Q34259205-E66A24EF-DA3E-4377-96B5-F81F027396FD Q34321979-2202D53B-F1A3-4B9B-AC10-B9F56C7D4AC2 Q34612281-3A7ABDE5-DD15-4DBC-8935-4628B27D34E4 Q34633885-458155B5-F07E-4496-9336-F70C6CCBB317 Q34646614-DF906603-D17B-4EE7-9042-DD93D17AB620 Q34662717-389CF5E7-AE75-47BD-B9D5-EF1C174AB443 Q34678882-3F92796B-2728-45CA-A8D0-4DD8A3853585 Q34801227-6A32A1AC-76E8-4045-ABE5-339E6E35A4EA Q34976858-D9B8E8AD-FD67-488E-90B8-CA8D5F319985 Q35024226-D449FDB2-2BD6-4721-993A-A66BE5647D3D Q35024230-45A09C58-ADA5-444D-9797-9EE1F464A0C4 Q35085738-D0278114-FAD6-4CD2-8AF8-B654CEAF7730 Q35097007-C09E5B28-C841-42F5-82F7-67619B72082D Q35324807-73FA3D8E-0B52-461D-BAD3-1791CBFF2FBF Q35446785-900BF39A-18CB-49C3-8293-0023385B730E Q35550888-9E2BA394-1A87-4ABC-8578-12CF75DD21BE Q35699289-C80AA66C-92F9-4765-911F-047734AEA322 Q35718310-7FEC58C9-9712-4505-AB32-20D41736DB6A Q35801085-C76E827E-3E40-4726-9C1D-543A5198A0FE Q35810176-63C6105C-DC02-4613-8949-FC7AA6FF3477 Q35847321-5993E18A-A6CD-4B00-8782-1701BE128E55 Q35859282-3D289F66-0E05-4A0F-B663-18665B1F68E8 Q35878248-E948419F-3CB2-4C4B-838B-107C4E7CC018

P2860

Improving melanoma classification by integrating genetic and morphologic features

http://www.wikidata.org/entity/Q33340639

description

2008 nî lūn-bûn

@nan

2008 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2008 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

name

Improving melanoma classification by integrating genetic and morphologic features

@ast

Improving melanoma classification by integrating genetic and morphologic features

@en

type

label

Improving melanoma classification by integrating genetic and morphologic features

@ast

Improving melanoma classification by integrating genetic and morphologic features

@en

prefLabel

Improving melanoma classification by integrating genetic and morphologic features

@ast

Improving melanoma classification by integrating genetic and morphologic features

@en

P1433

Q33340639-A5656E6F-F6AD-4CA3-A77D-891C970AF0D0

P1476

Q33340639-056961D7-A61D-48E9-BBD1-38984FE79784

P2093

Q33340639-C3710935-B467-4F2C-9386-7DD3237C0FDC

Q33340639-D17BA108-9EA1-42E5-A9EF-2F25238C2881

Q33340639-D2B88F76-E46D-438E-9C22-1D79B2EA8B48

Q33340639-F370E4A0-179C-49F9-B2DA-B46E10272B16

P2860

Q33340639-001AC1CF-ABED-442D-B56B-DDC799A3D2E9

Q33340639-100D5FE2-29BE-482B-BAB4-8B0A1D1ED914

Q33340639-1B745E17-C960-4500-96EE-8FDFC84865EC

Q33340639-1E988867-A1DA-41B7-B159-730A3602E491

Q33340639-1F97085A-20DD-42BE-8B54-FD813AD01129

Q33340639-20E72EE1-A3C8-4466-A52E-174D2B62CC4D

Q33340639-33F2EBCA-5E89-438E-BB2F-829DA6677FBA

Q33340639-346884A8-0915-41DC-A5A3-8522F3A9ADD9

Q33340639-3E0668CC-A61A-4277-A4B1-5C5A34E84FB8

Q33340639-472A0E13-5552-46DE-A3E7-1F0765ADEA47

P304

Q33340639-4A615BD5-9178-4C16-B89A-A9D9A9CB0567

P31

Q33340639-17B7BCED-7996-443B-85E8-C766A3616DB4

P356

Q33340639-1DBDE814-DBC8-4F32-8B83-68D6CD348CCF

P407

Q33340639-C10601E2-E618-4E3C-BC13-9293AA1DC455

P433

Q33340639-4A6A5592-FA91-465F-91EC-CBD21BEC2FA4

P478

Q33340639-60459185-27C7-4509-8E39-04D973EC8447

P50

Q33340639-35A66682-8B44-4046-A9E2-C2FBDAF31B6D

Q33340639-C8DDF3DC-B938-47BB-83F9-2B2F333D465D

Q33340639-FA2BAA9A-1E08-4530-8753-3095AEBCDC8E

P577

Q33340639-07B1A730-3513-4570-920D-F0CA3D1B5F07

P5875

Q33340639-DF9CD3D2-7E04-48EE-8244-6F7590E875DA

P698

Q33340639-223E1106-2FDF-4076-AD93-294835E3A034

P932

Q33340639-EE230F58-B423-4AFD-96E3-12C23EFAF27C

P356

JOURNAL.PMED.0050120

P1433

P1476

Improving melanoma classification by integrating genetic and morphologic features

@en

P2093

Amaya Viros

http://www.w3.org/2001/XMLSchema#string

Daniel Pinkel

http://www.w3.org/2001/XMLSchema#string

Jane Fridlyand

http://www.w3.org/2001/XMLSchema#string

Konstantin Lasithiotakis

http://www.w3.org/2001/XMLSchema#string

P2860

Thickness, cross-sectional areas and depth of invasion in the prognosis of cutaneous melanoma

Clinical significance of BRAF mutations in metastatic melanoma

The Measurement of Observer Agreement for Categorical Data

Determinants of BRAF mutations in primary melanomas

Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma

Distinct sets of genetic alterations in melanoma

NRAS and BRAF mutations arise early during melanoma pathogenesis and are preserved throughout tumor progression.

High frequency of BRAF mutations in nevi.

Somatic activation of KIT in distinct subtypes of melanoma.

The clinical diagnosis of malignant melanoma.

P304

e120

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1371/JOURNAL.PMED.0050120

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

5

http://www.w3.org/2001/XMLSchema#string

P50

Boris C. Bastian

P577

2008-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

5324553

http://www.w3.org/2001/XMLSchema#string

P698

18532874

http://www.w3.org/2001/XMLSchema#string

P932

2408611

http://www.w3.org/2001/XMLSchema#string